Skip to content

Opening book details…

Can I read Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors on EtoBox?

Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors by Leonard H. Wexler; Thomas F. DeLaney; Maria Tsokos; Nilo Avila; Seth M. Steinberg; Linda Weaver-McClure; Joan Jacobson; Paul Jarosinski; Yasmine M. Hijazi; Frank M. Balis; Marc E. Horowitz is a Medicine article available to read on EtoBox.

What is Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors about?

This study was conducted to determine the feasibility of, and improve outcome by, incorporating ifosfamide and etoposide (IE) into the therapy of newly diagnosed patients with Ewing's sarcoma family of tumors of bone and soft tissue. ## METHODS. Fifty-four newly diagnosed patients received 7 cycles of vincristine, doxorubicin, and cyclophosphamide (VAdriaC) and 11 cycles of IE. Radiation therapy after the fifth chemotherapy cycle was the primary approach to local control. ## RESULTS. Actuarial 5-year event-free survival (EFS) and overall survival rates were 42% and 45%, respectively, with a median duration of potential follow-up of 6.8 years. EFS was significantly better for patients with localized tumors than for those with metastatic lesions (64% v. 13%, P < 0.0001). Actuarial local progression-free survival at 5 years was 74%, and did not correlate with primary tumor size or site, histologic subtype, or the presence of metastases. Febrile neutropenia developed after 49% of cycles, and clinical or sub-clinical cardiac dysfunction was common (7% and 40% respectively). There were four toxic deaths and one case of secondary myelodysplastic syndrome. ## CONCLUSIONS. Despite substanti

Who reads Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors?

It is typically read by researchers, students, and practitioners in Medicine.

Author
Leonard H. Wexler; Thomas F. DeLaney; Maria Tsokos; Nilo Avila; Seth M. Steinberg; Linda Weaver-McClure; Joan Jacobson; Paul Jarosinski; Yasmine M. Hijazi; Frank M. Balis; Marc E. Horowitz
Publisher
John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley (ISSN 0008-543X)
Published
1996
Language
EN
Field
Medicine (Health Sciences)

More by Leonard H. Wexler; Thomas F. DeLaney; Maria Tsokos; Nilo Avila; Seth M. Steinberg; Linda Weaver-McClure; Joan Jacobson; Paul Jarosinski; Yasmine M. Hijazi; Frank M. Balis; Marc E. Horowitz

Browse all works by Leonard H. Wexler; Thomas F. DeLaney; Maria Tsokos; Nilo Avila; Seth M. Steinberg; Linda Weaver-McClure; Joan Jacobson; Paul Jarosinski; Yasmine M. Hijazi; Frank M. Balis; Marc E. Horowitz